重症肌無力治療市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

2024 年全球重症肌無力治療市場價值為 18 億美元，預計到 2034 年將以 7.6% 的複合年成長率成長，達到 38 億美元。這一穩定的成長軌跡反映了全球對重症肌無力的認知不斷提高，重症肌無力是一種以骨骼肌無力為特徵的自身免疫性神經肌肉疾病。隨著已開發地區和新興地區的診斷能力不斷提高，疾病的早期發現變得越來越頻繁。這導致對及時有效的治療干預的需求激增。老年人口的不斷成長是導致病例數量上升的關鍵因素，由於老年人的免疫系統自然衰退，他們更容易患上自體免疫疾病。

此外，患者對非侵入性藥物治療而非手術治療的偏好也推動了對創新療法的需求不斷成長。醫療支出的增加、優惠的報銷政策以及政府對罕見疾病管理的支持進一步推動了重症肌無力治療市場的擴張。隨著製藥公司加強對研發的投資，將先進的治療方案推向市場，競爭格局也正在轉變。藥品製造商優先考慮標靶治療，以改善生活品質並減少副作用，而生物技術公司和醫療機構之間的合作則支持更快的創新。這些因素共同表明，市場將在患者需求和技術進步的推動下實現長期永續成長。

市場按治療類型細分，包括藥物治療、療法和手術。其中，藥品部門預計將推動最大佔有率的收入成長，預計複合年成長率為 7.7%，市場價值預計到 2034 年將達到 29 億美元。全球重症肌無力病例的激增增加了對可靠藥物治療的需求，包括單株抗體和免疫抑制劑。同時，靜脈注射免疫球蛋白 (IVIG) 和血漿置換等療法因其在治療中度至重度症狀方面的臨床效果而越來越受歡迎。

根據分銷管道，市場分為醫院藥房、零售藥房和電子商務平台。醫院藥局佔了相當大的佔有率，2024 年的收入將達到 10 億美元。這種成長主要是由於人們對需要醫療監督和專門管理的生物療法的偏好日益增加。此外，先進生物治療的保險覆蓋範圍也支持基於醫院的分銷模式。

2024 年美國重症肌無力治療市值為 7.333 億美元。美國 FDA 的監管支持（包括快速核准和孤兒藥指定）正在鼓勵新療法的推出。在領先製藥公司的支持下，美國醫療保健生態系統在推動創新和改善患者治療效果方面繼續發揮關鍵作用。

該行業的主要參與者包括強生、輝瑞、Alexion Pharmaceuticals、安進、艾伯維、安斯泰來製藥、梯瓦製藥工業、羅氏製藥、三菱田邊製藥公司、UCB 製藥、基立福、葛蘭素史克、諾華、賽諾菲和博士倫製藥公司。這些公司正在積極擴大其治療管道，重點關注單株抗體、免疫抑制劑和策略合作夥伴關係，以推進研發並簡化全球患者的市場准入。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

• 產業生態系統分析
• 產業衝擊力
  • 成長動力
    • 重症肌無力盛行率上升
    • 生物療法的進展
    • 老年人口不斷增加
    • 有利的監管批准和研究資金
  • 產業陷阱與挑戰
    • 治療費用高昂
    • 認知不足和誤診
• 成長潛力分析
• 監管格局
• 技術格局
• 管道分析
• 未來市場趨勢
• 差距分析
• 波特的分析
• PESTEL分析

第4章：競爭格局

• 介紹
• 公司市佔率分析
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 策略儀表板

第5章：市場估計與預測：按治療類型，2021 - 2034 年

• 主要趨勢
• 藥物
  • 膽鹼酯酶抑制劑
  • 皮質類固醇
  • 免疫抑制劑
  • 單株抗體
• 治療
  • 靜脈注射免疫球蛋白（IVIG）
  • 血漿置換
• 手術

第6章：市場估計與預測：依疾病類型，2021 - 2034 年

• 主要趨勢
• 眼部重症肌無力
• 全身性重症肌無力

第7章：市場估計與預測：按配銷通路，2021 - 2034 年

• 主要趨勢
• 醫院藥房
• 零售藥局
• 電子商務

第8章：市場估計與預測：按地區，2021 - 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第9章：公司簡介

• AbbVie
• Alexion Pharmaceuticals
• Amgen
• Argenx
• Astellas Pharma
• Bausch Health Companies
• F. Hoffmann-La Roche
• GlaxoSmithKline
• Grifols
• Mitsubishi Tanabe Pharma Corporation
• Novartis
• Pfizer
• Sanofi
• Teva Pharmaceutical Industries
• UCB Pharma

The Global Myasthenia Gravis Treatment Market was valued at USD 1.8 billion in 2024 and is estimated to grow at a CAGR of 7.6% to reach USD 3.8 billion by 2034. This steady growth trajectory reflects a rising global awareness of myasthenia gravis, an autoimmune neuromuscular disorder marked by weakness in the skeletal muscles. As diagnostic capabilities continue to improve across developed and emerging regions, early-stage identification of the disease is becoming more frequent. This is prompting a surge in the demand for timely and effective treatment interventions. The growing elderly population, who are more prone to autoimmune diseases due to a naturally declining immune system, is playing a key role in driving case numbers upward.

Additionally, evolving patient preferences for non-invasive, pharmaceutical-based treatments over surgical options are contributing to the rising demand for innovative therapies. Increased healthcare expenditure, favorable reimbursement policies, and government support for rare disease management are further fueling the expansion of the myasthenia gravis treatment market. The competitive landscape is also witnessing a shift as pharmaceutical companies invest more aggressively in research and development to bring advanced treatment options to market. Drug manufacturers are prioritizing targeted therapies to improve quality of life and reduce side effects, while collaborations between biotech firms and medical institutions are supporting faster innovation. These elements collectively point to a market that is poised for long-term, sustainable growth driven by both patient needs and technological progress.

The market is segmented by treatment types, including medication, therapy, and surgery. Among these, the medication segment is expected to drive the largest portion of revenue growth, with a projected CAGR of 7.7% and a market value forecast to reach USD 2.9 billion by 2034. The surge in global cases of myasthenia gravis is increasing the demand for reliable pharmaceutical treatments, including monoclonal antibodies and immunosuppressants. In parallel, therapies such as intravenous immunoglobulin (IVIG) and plasmapheresis are gaining popularity due to their clinical effectiveness in managing moderate to severe symptoms.

Based on distribution channels, the market is categorized into hospital pharmacies, retail pharmacies, and e-commerce platforms. Hospital pharmacies accounted for a significant share, with revenues reaching USD 1 billion in 2024. This growth is largely due to the rising preference for biologic therapies that require medical supervision and specialized administration. Additionally, insurance coverage for advanced biological treatments is supporting hospital-based distribution models.

The U.S. Myasthenia Gravis Treatment Market was valued at USD 733.3 million in 2024. Regulatory support from the U.S. FDA, including fast-track approvals and orphan drug designations, is encouraging the launch of new therapies. The U.S. healthcare ecosystem, backed by leading pharmaceutical firms, continues to play a crucial role in pushing forward innovation and improving patient outcomes.

Key players in the industry include Johnson & Johnson, Pfizer, Alexion Pharmaceuticals, Amgen, AbbVie, Astellas Pharma, Teva Pharmaceutical Industries, F. Hoffmann-La Roche, Mitsubishi Tanabe Pharma Corporation, UCB Pharma, Grifols, GlaxoSmithKline, Novartis, Sanofi, and Bausch Health Companies. These companies are actively expanding their treatment pipelines with a focus on monoclonal antibodies, immunosuppressants, and strategic partnerships to advance R&D and streamline market access for patients worldwide.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of myasthenia gravis
    • 3.2.1.2 Advancements in biologic therapies
    • 3.2.1.3 Growing geriatric population
    • 3.2.1.4 Favorable regulatory approvals and research funding
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of treatment
    • 3.2.2.2 Limited awareness and misdiagnosis
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technology landscape
• 3.6 Pipeline analysis
• 3.7 Future market trends
• 3.8 Gap analysis
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Medication
  • 5.2.1 Cholinesterase inhibitors
  • 5.2.2 Corticosteroids
  • 5.2.3 Immunosuppressants
  • 5.2.4 Monoclonal antibodies
• 5.3 Therapy
  • 5.3.1 Intravenous immunoglobulin (IVIG)
  • 5.3.2 Plasmapheresis
• 5.4 Surgery

Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Ocular myasthenia gravis
• 6.3 Generalized myasthenia gravis

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacies
• 7.3 Retail pharmacies
• 7.4 E-commerce

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 AbbVie
• 9.2 Alexion Pharmaceuticals
• 9.3 Amgen
• 9.4 Argenx
• 9.5 Astellas Pharma
• 9.6 Bausch Health Companies
• 9.7 F. Hoffmann-La Roche
• 9.8 GlaxoSmithKline
• 9.9 Grifols
• 9.10 Mitsubishi Tanabe Pharma Corporation
• 9.11 Novartis
• 9.12 Pfizer
• 9.13 Sanofi
• 9.14 Teva Pharmaceutical Industries
• 9.15 UCB Pharma